Odyssey Group International (ODYY) 10-K 23 Oct 19 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Jul. 31, 2019	Oct. 23, 2019	Jan. 31, 2019
Document And Entity Information
Entity Registrant Name	Odyssey Group International, Inc.
Entity Central Index Key	0001626644
Document Type	10-K
Document Period End Date	Jul. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--07-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Non-accelerated Filer
Entity Public Float			$ 25,735,000
Entity Common Stock, Shares Outstanding		86,990,400
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019
Entity Small Business	true
Entity Emerging Growth	false
Entity Shell Company	false
Entity Interactive data current	Yes
Entity File Number	333-200785
Entity Incorporation State Country Code	NV

Balance Sheets

Balance Sheets - USD ($)	Jul. 31, 2019	Jul. 31, 2018
Current Assets:
Cash and cash equivalents	$ 167,095	$ 390
Prepaid expenses	302,833	0
Loan receivable	50,000	0
Total Current Assets	519,928	390
Property and equipment, net	1,517	2,069
Intangible assets, net	23,139,570	25,000
Total Assets	23,661,015	27,459
Current liabilities:
Accounts payable	47,743	26,691
Accrued wages	297,547	188,500
Contingent Liability	144,000	0
Note payable, including accrued interest	784,913	631,645
Total liabilities	1,274,203	846,836
Stockholders' equity (deficiency):
Preferred stock, $.001 par value; 100,000,000 shares authorized, no shares issued or outstanding	0	0
Common stock, $.001 par value; 500,000,000 shares authorized with 86,990,400 and 61,414,000 issued and outstanding	86,990	61,414
Additional paid-in capital	23,821,124	192,086
Deficit	(1,521,302)	(1,072,877)
Total stockholders' equity (deficiency)	22,386,812	(819,377)
Total Liabilities and stockholders' equity (deficiency)	$ 23,661,015	$ 27,459

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Jul. 31, 2019	Jul. 31, 2018
Statement of Financial Position [Abstract]
Preferred Stock, Par Value	$ 0.001	$ .001
Preferred Stock, Shares Authorized	100,000,000	100,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par Value	$ 0.001	$ .001
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Shares Issued	86,990,400	61,414,000
Common Stock, Shares Outstanding	86,990,400	61,414,000

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Income Statement [Abstract]
Revenues	$ 0	$ 0
Cost of goods sold	0	0
Gross profit	0	0
General and administrative expenses	378,143	288,995
Impairment loss	0	131,447
Loss from operations	(378,143)	(420,442)
Interest expense	(70,282)	(62,673)
Net loss	$ (448,425)	$ (483,115)
Basic net loss per share:	$ (0.01)	$ 0
Weighted average number of shares	69,898,436	117,128,060

Statements of Stockholders' Equ

Statements of Stockholders' Equity (Deficiency) - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning balance, shares at Jul. 31, 2017	114,839,600
Beginning balance, value at Jul. 31, 2017	$ 114,840	$ 55,060	$ (589,762)	$ (419,862)
Debt converted to common stock, shares	1,574,000
Debt converted to common stock, value	$ 1,574	32,026	0	33,600
Common stock issued for services, shares	5,000,000
Common stock issued for services, value	$ 5,000	45,000	0	50,000
Common stock restructure, shares	(60,000,000)
Common stock restructure, value	$ (60,000)	60,000		0
Net loss			(483,115)	(483,115)
Ending balance, shares at Jul. 31, 2018	61,414,000
Ending balance, value at Jul. 31, 2018	$ 61,414	192,086	(1,072,877)	(819,377)
Note payable converted to common stock, shares	2,531,400
Note payable converted to common stock, value	$ 2,531	22,783		25,314
Common stock issued for services, shares	321,000
Common stock issued for services, value	$ 321	$ 331,929		$ 332,250
Common stock issued for compensation, shares	4,720,000
Common stock issued for compensation, value	4,720	67,280		72,000
Common stock issued for acquisition of intangible assets, shares	18,004,000
Common stock issued for acquisition of intangible assets, value	$ 18,004	$ 22,486,996		$ 22,505,000
Common stock options issued for acqusition of intangiable assets		506,400		506,400
Warrants issued in connection with convertible notes		13,075		13,075
Beneficial conversion feature related to convertible notes		200,575		200,575
Net loss			(448,425)	(448,425)
Ending balance, shares at Jul. 31, 2019	86,990,400
Ending balance, value at Jul. 31, 2019	$ 86,990	$ 23,821,124	$ (1,521,302)	$ 22,386,812

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Operating activities
Net loss	$ (448,425)	$ (483,115)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	41,381	10,551
Impairment loss	0	131,447
Stock based payment expense for consulting and compensation	101,417	0
Debt discount	408	0
Changes in operating assets and liabilities:
Increase in accounts payable	21,053	47,882
Increase in accrued wages	109,047	84,500
Increase in accrued interest	70,282	62,673
Net cash used in operating activities	(104,837)	(146,062)
Investing activities
Net cash used in investing activities	0	0
Financing activities
Proceeds from notes payable	271,542	133,026
Net cash provided by financing activities	271,542	133,026
Net change in cash and cash equivalents	166,705	(13,036)
Cash and cash equivalents, beginning of year	390	13,426
Cash and cash equivalents, end of year	167,095	390
Noncash transactions:
Common stock issued for acquisition of intangible assets	22,505,000	0
Common stock issued for consulting services	332,250	50,000
Benefical conversion feature related to convertible notes	213,650	0
Contingent liability related to acquisition of intangible assets	144,000	0
Accounts payable transferred to note payable	25,314	15,000
Debt converted to Common Stock	0	60,000
Stock restructure- Common stock	$ 0	$ 36,500

1. Nature of Operations

1. Nature of Operations	12 Months Ended
	Jul. 31, 2019
Accounting Policies [Abstract]
Nature of Operations	1. Nature of Operations The corporate mission is to create or acquire distinct assets, intellectual property, and technologies with an emphasis on acquisition targets that generate positive cash flow. Our business model is to develop or acquire medical related products, engage third parties to manufacture such products and then distribute the products through various distribution channels, including third parties. The Company has significant assets in three different life saving technologies; the CardioMap® heart monitoring and screening device, the Save a Life choking rescue device and a unique neurosteroid drug compound intended to treat rare brain disorders. We intend to acquire other technologies and assets and plan to be a trans-disciplinary product development company involved in the discovery, development and commercialization of products and technologies that may be applied over various medical markets. We intend to license, improve and/or develop our products and identify and select distribution channels. We intend to establish agreements with distributors to get products to market quickly as well as to undertake and engage in our own direct marketing efforts. We will determine the most effective method of distribution for each unique product that we include in our portfolio. We intend to engage third party research and development firms who specialize in the creation of our products to assist us in the development of our own products We intend to apply for trademarks and patents once we have developed proprietary products. We are not currently selling or marketing any products, as our product is in late stage development and Food and Drug Administration ("FDA") clearance or approval to market the product will be required in order to sell in the United States.

2. Summary of Significant Accou

2. Summary of Significant Accounting Policies	12 Months Ended
	Jul. 31, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Use of estimates The preparation of financial statements in conformity with Generally Accepted Accounting Principles (“GAAP”) generally requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Basis of accounting The Company has not elected to adopt the option available under GAAP to measure any of its eligible financial instruments or other items at fair value. Accordingly, the Company measures all of its assets and liabilities on the historical cost basis of accounting unless otherwise required by GAAP. Accounts receivable Accounts receivable are carried at original invoice amount less an estimated allowance for doubtful accounts, if deemed necessary by management. An allowance for doubtful accounts is based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful accounts, if any, by identifying troubled accounts and by using historical experience applied to an aging of accounts. Property and equipment, net Property and equipment is stated at cost less accumulated depreciation. Depreciation is recorded on a straight-line basis over the estimated useful lives of the assets. For the year ended July 31, 2019 and 2018 the Company recognized depreciation expense of $552. Beneficial Conversion Feature of convertible notes payable The Beneficial Conversion Feature ("BCF") of a convertible note is normally characterized as the convertible portion or feature of certain notes payable that provide a rate of conversion that is below market value or in-the-money when issued. The Company records a BCF related to the issuance of a convertible note when issued and also records the estimated fair value of any warrants issued with those convertible notes. Beneficial conversion features that are contingent upon the occurrence of a future event are recorded upon the occurrence of the event. The BCF of a convertible note is measured by allocating a portion of the note's proceeds to the warrants, if applicable, and as a reduction of the carrying amount of the convertible note equal to the intrinsic value of the conversion feature, both of which are credited to additional paid-in-capital. The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on an allocated fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense. Net loss per share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. No fully diluted loss per share is presented, because it would be anti-dilutive. Revenue recognition The Company recognizes revenue when control is transferred to the customer. For products sold through direct sales representatives, control is transferred upon shipment or upon delivery, based on the contract terms and legal requirements. Payment terms vary depending on the country of sale, type of customer, and type of product. If a contract contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative standalone selling price. Shipping and handling is treated as a fulfillment activity rather than a promised service, and therefore, is not considered a performance obligation. Taxes assessed by a governmental authority that are both imposed on, and concurrent with, a specific revenue producing transaction and collected by the Company from customers (for example, sales, use, value added, and some excise taxes) are not included in revenue. For contracts that have an original duration of one year or less, the Company uses the practical expedient applicable to such contracts and does not adjust the transaction price for the time value of money. We are not currently selling or marketing any products, as our product is in late stage development and FDA clearance to market the product will be required in order to sell in the United States.

3. Impact of New Accounting Pro

3. Impact of New Accounting Pronouncements	12 Months Ended
	Jul. 31, 2019
Accounting Changes and Error Corrections [Abstract]
Impact of New Accounting Pronouncements	3. Impact of New Accounting Pronouncements Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”), in the form of Accounting Standards Updates (“ASUs”), to the FASB’s Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. The FASB issued ASU 2017-11, Earnings Per Share (Topic 260) effective for annual reporting periods beginning after December 15, 2018. The amendments update the change in the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. This new guidance is effective for interim and annual reporting periods beginning after December 15, 2018 and interim periods, with early adoption permitted. The Company will adopt the standard as of August 1, 2019 and does not expect the adoption to have a material impact on the Company’s financial statements and disclosures. The FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting, effective for annual reporting periods beginning after December 15, 2017 adopting this standard on its consolidated financial statements. The ASU amends the scope of modification accounting for share-based payment arrangements, provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting. The new guidance will allow companies to make certain changes to awards without accounting for them as modifications. It does not change the accounting for modifications. The new guidance will be applied prospectively to awards modified on or after the adoption date. This new guidance is effective for interim and annual reporting periods beginning after December 15, 2018. The Company will adopt the standard as of August 1, 2019 and does not expect the adoption to have a material impact on the Company’s financial statements and disclosures. The FASB issued ASU 2016-02, Leases (Topic 842), which is intended to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The guidance requires lessees and lessors to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. ASU 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods, with early adoption permitted. The Company will adopt the standard as of August 1, 2019 and does not expect the adoption to have a material impact on the Company’s financial statements and disclosures.

4. Intangible Assets - Patent

4. Intangible Assets - Patent and Distribution Rights	12 Months Ended
	Jul. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets - Patent and Distribution Rights	4. Intangible Assets – Patent and Distribution Rights FASB ASC 820, "Fair Value Measurements and Disclosures", establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under FASB ASC 820 are described as follows: Level 1 – Observable inputs, such as unadjusted quoted prices in active markets, for substantially identical assets and liabilities. Level 2 – Observable inputs other than quoted prices within Level 1 for similar assets and liabilities. These include quoted prices for similar assets and liabilities in active markets, quoted prices for identical assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data. If the asset or liability has a specified or contractual term, the input must be observable for substantially the full term of the asset or liability. Level 3 – Unobservable inputs that are supported by little or no market activity, generally requiring a significant amount of judgment by management. The assets or liabilities fair value measurement level within the fair value hierarchy is based on the lowest level. The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Further, although the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date. The Company purchased distribution rights to sell and distribute a new technology, CardioMap®, which is an advanced technology for early non-invasive testing for heart disease. The product distribution rights are amortized over the life of the underlying patent. The acquisition cost of $18.75 million (Level 2) is valued at the fair market value of $1.25 per share for the stock granted on the date of acquisition. The Company acquired the intellectual property, know-how and patents for an anti-choking, life-saving medical device from Dr. James De Luca (“De Luca”), inventor and Murdock Capital Partners (“MCP”). The asset is valued at $675,400 (Level 2), which includes the fair market value of $1.25 per share for the stock granted on the date of acquisition, as well as stock options granted valued at $0.84 per share based upon the Black-Scholes valuation model and a onetime cash payment totaling $250,000 that will be paid upon FDA clearance of the product. The payment is recorded as a contingent liability and, based upon an independent valuation of the patents (Level 3), at July 31, 2019, the payment has a fair market value of $144,000. The intellectual property, know-how and patents are being amortized over the life of the patents. The Company acquired the patented chemical compound for a neurosteroid as part of the joint venture agreement with Prevacus, Inc. The acquisition cost of $3.73 million (Level 2) is being amortized over the life of the patent. The asset is valued at the fair market value of $1.25 per share for the stock granted on the date of acquisition. The patents are being amortized over the life of the patents. For the year ended July 31, 2019 the gross carrying amount of the intangible assets totaled $23,205,400 and accumulated amortization totaled $65,830 for a net amount of $23,139,570. Amortization expense recognized for the year ended July 31, 2019 and 2019 is $40,830 and $10,000, respectively. Patents are amortized over their useful lives with the weighted average years remaining of 10.73 with no residual value. Amortization is as follows over the next five years and thereafter: Year Ending July 31, Patents Year 1 $ 2,039,003 Year 2 2,034,003 Year 3 2,029,003 Year 4 2,029,003 Year 5 2,029,003 Thereafter 12,979,557

5. Notes Payable

5. Notes Payable	12 Months Ended
	Jul. 31, 2019
Debt Disclosure [Abstract]
Notes Payable	5. Notes Payable As of July 31, 2019, the Company has a note payable that is subject to periodic payments that come due based on sales. The note fully matures in January 2020, bears interest at 12.5% annually, and the remaining unpaid balance is convertible upon maturity at the holder’s option into shares of common stock at a conversion price fixed at $0.01 per share. As of July 31, 2019, the note has a balance of $747,608. Because the conversion feature does not meet the criteria for characterization as a beneficial conversion feature, no portion of the proceeds from the issuance of the note was accounted for as attributable to the conversion feature. This note was amended on February 1, 2018, where the debt holder agreed to convert portions of its loan pari passu with any new investment raise of $500,000 or more. Furthermore, the debt holder was issued a common stock warrant for 4 million shares at $0.25 per share with an expiration date of 90 days after the issuance, as consideration to the debt holder to agree to begin to convert portions of its loan to common stock pari passu with a new offering raise of investment at a minimum of $500,000. As of July 31, 2019, these warrants expired. As of July 31, 2019, the Company has three additional convertible debt notes outstanding. The notes bear interest at 7.0% annually and the entire outstanding principal amount, together with accrued interest shall become due and payable on the date that is one (1) year from the date of issuance, unless before such date, is converted into shares of capital stock of the Company. At the option of the holder, the principal amount of the notes and any accrued interest may be converted into shares of common stock at a conversion price of $1.00 per share or at a 10% discount to the closing price on the day of conversion, but not lower than $0.50 cents per share. At maturity, and subject to a trickle out agreement, the Company shall have the right to either pay off the loan and any interest accrued or convert the loan amount and any interest into shares of common stock. The debt holders were issued a common stock warrant equal to 10% of the note with a price of $1.50 per share and a term for one year from the investment date. At July 31, 2019, the notes have a balance of $37,305. Because the conversion feature met the criteria for characterization as a beneficial conversion feature, a portion of the proceeds, including warrants, of $213,650 from the issuance of the notes are accounted for as attributable to the conversion feature.

6. Fair Value Measurements

6. Fair Value Measurements	12 Months Ended
	Jul. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	6. Fair Value Measurements The carrying values of cash, the note receivable, and notes payable approximate their estimated fair values because of the short-term nature of these instruments.

7. Common Stock

7. Common Stock	12 Months Ended
	Jul. 31, 2019
Equity [Abstract]
Common Stock	7. Common Stock For the year ended July 31, 2018, the Company’s Board approved the return of 60 million shares from the founding common stockholders. On December 11, 2018, the Company amended the employment agreement of J. Michael Redmond to further document and incorporate the transition of the control of the Green Energy Alternatives stock. In the amendment, the Company agrees to issue Mr. Redmond a total of 10 million shares of the Company’s common stock. At least 4.7 million stock grants were granted to Mr. Redmond from the Company, and 5.3 million shares have been assigned to Mr. Redmond through control of Green Energy Alternatives, LLC. The Company recognized $47,000 of compensation expense related to the 4.7 million shares granted, with an estimated fair value of $0.01 per share, for the year ended July 31, 2019. On January 9, 2019, Vivakor, Inc. (“Vivakor”) gave written notice to the Company effecting a conversion of $25,314 of convertible debt into 2,531,400 shares of Common Stock of the Company, issued to Vivakor pursuant to the Master Revolving Note, dated as of January 4, 2017, and amended as of February 1, 2018, by and between the Company and Vivakor. On April 17, 2019, the Company entered into an agreement for consulting services to be provided through April 2020. The Company granted the consultant 100,000 shares of the Company’s common stock. On May 22, 2019, the Company entered into employment agreements for two part-time employees. The Company granted the employees 10,000 shares each of the Company’s common stock. On March 22, 2019, April 17, 2019, June 1, 2019, and July 26, 2019, the Company entered into agreements for consulting services for the next 12 months. The Company granted the consultants a total of 305,000 shares of the Company’s common stock. On June 27, 2019, Odyssey entered into a Definitive Agreement with Prevacus to form a Joint Venture relating to the development of a neurosteroid for treating two orphan disorders, ALS and Niemann Picks disease. Prevacus contributed to the JV, the chemical compound and Odyssey is be responsible for funding the JV through Phase One clinical trials. The JV company will own the patents. Each party will own the JV company equally. In addition to the JV, the two companies have entered into a share exchange agreement whereby Prevacus will receive three million shares of Odyssey common stock and Odyssey will receive one million shares of Prevacus stock. The chemical compound for the neurosteroid being developed has issued patents, and as consideration for the patented compound, Odyssey issued Prevacus two million shares of its common stock. As part of the Agreement, Dr. Jacob Vanlandingham Ph.D., CEO of Prevacus, was issued one million shares of the Company’s common stock. The Company allocated 984,000 shares to the acquisition of the patent and 20,000 shares were allocated to Dr. Vanlandingham as a Director of the Company. On June 27, 2019, Odyssey entered into a Definitive Agreement with Dr. James De Luca, inventor and Murdock Capital Partners, advisors to De Luca, to acquire the intellectual property, know-how and patents for a life-saving medical device currently in development. The Company acquired intellectual property rights, namely, United States Letters Patent No. 7,559,921, entitled “Device for Removing a Lodged Mass” which issued on July 14, 2009 and which was reissued on June 2, 2015 and received U.S. Reissue Patent No. Re 45,535 and United States Patent Number 8,454,624 also entitled “Device for Removing a Lodged Mass” which was issued on June 4, 2013. As consideration for the patent and intellectual property, the Company granted stock options totaling 600,000 shares of the Company’s stock, vesting on certain milestones. The options will be split between De Luca and MCP. The Company also granted De Luca, 20,000 common shares. A onetime cash payment totaling $250,000 will be paid to Deluca and MCP upon FDA clearance of the product. The payment is recorded as a contingent liability and, based upon an independent valuation of the patents, at July 31, 2019, the payment has a fair market value of $144,000.

8. Stock Based Compensation

8. Stock Based Compensation	12 Months Ended
	Jul. 31, 2019
Share-based Payment Arrangement [Abstract]
Stock Based Compensation	8. Stock Based Compensation We have not adopted any equity compensation plans. We have entered into an individual compensation plan for Mr. Redmond, for which Mr. Redmond has been granted stock options of 15 million shares at $0.25 per share. The options vest upon achieving the following milestones: 5 million options vest upon each milestone, when the Company obtains revenue of $5 million, $10 million and $15 million. Mr. Redmond cannot sell any of the above stock options for two years from the effective date of the employment agreement or until the Company reaches $10 million in annual revenue, whichever occurs first. The stock option vesting accelerates and becomes immediately exercisable upon the sale, merger or any transaction resulting in the majority (more than 50%) of the Company stock being obtained. The Company has not recorded any expense, as we have not determined that it is probable that the milestones will be achieved.

9. Income Taxes

9. Income Taxes	12 Months Ended
	Jul. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	9. Income Taxes We expect to file income tax returns in the U.S. federal jurisdiction and various state jurisdictions in which we operate and are currently not under examination. As of July 31, 2019, and 2018, the Company had net deferred tax assets of $260,247 and $309,859 consisting of net operating loss carryforwards that expire in 2035 net of an effective offsetting valuation allowance of 100%. Our effective tax rate for 2019 and 2018 is 21%. The Company has established the valuation allowance because due to substantial uncertainty as to the Company’s ability to continue as a going concern (Note 10), it is more likely than not at this time that the deferred tax assets will not be realized within the carryforward period.

10. Going Concern

10. Going Concern	12 Months Ended
	Jul. 31, 2019
Risks and Uncertainties [Abstract]
Going Concern	10. Going Concern We have a deficit of $1,521,302 as of July 31, 2019. For the foreseeable future, we expect to experience continuing operating losses and negative cash flows from operations as our management executes our current business plan. The cash available at July 31, 2019, may not provide enough working capital to meet our current operating expenses through October 23, 2020, as we continue to accrue overhead expenses. We will need to raise additional capital through a debt financing or equity offering to meet our operating and capital needs. There can be no assurance, however, that we will be successful in our fundraising efforts or that additional funds will be available on acceptable terms, if at all. If we are unable to raise additional capital by October 23, 2020, we will adjust our current business plan. Due to our lack of additional committed capital, recurring losses, negative cash flow and accumulated deficit, there is substantial doubt about the Company’s ability to continue as a going concern.

11. Related Party Transactions

11. Related Party Transactions	12 Months Ended
	Jul. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	11. Related Party Transactions The Company has a common officer with Green Energy Alternatives, Inc. As of July 31, 2019, and 2018, Green Energy Alternatives, Inc. held 5.3 million shares of the Company’s common stock.

12. Subsequent Events

12. Subsequent Events	12 Months Ended
	Jul. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent Events We have evaluated subsequent events and, except for the transaction described below, there were no other events relative to the financial statements that require additional disclosure. On August 6, 2019, the Company entered into a convertible note payable for $100,000. The notes bear interest at 7.0% annually and mature automatically. The entire outstanding principal amount, together with accrued interest shall become due and payable on the date that is one (1) year from the date of issuance, unless converted into shares of capital stock of the Company. Warrants equal to 10% of the shares purchased with a price of $1.50 per share were issued to the note holders. The price of the warrant is $1.50 per share and the term is for one year from the investment date. On August 15, 2019, the Company amended its agreement with its financial consultant to included monthly payments of $5,000 and 200,000 stock options to be granted stock in accordance with the mutual agreement of the Board’s compensation committee. On August 20, 2019, the Company entered into a consulting agreement for research and development associated with the CardioMap®. The consultant will receive monthly payments of $5,000 and 2.0 million stock options, vesting upon certain milestone achievements. On August 28, 2019, Jeff Conroy joined the Board of Odyssey as an independent director. Mr. Conroy is an operating and business development executive with over 30 years in the life science industry across therapeutics and medical devices. Mr. Conroy is the Chairman & CEO of Embody, a DARPA-funded medical device company developing regenerative implants for tendon and ligament repair. Since 2012, he has served as the Head of Corporate Development for Especificos Stendhal S.A. de C.V., a Latin American specialty pharmaceutical company. He is the Managing Director of Windward Investments - structuring licensing partnerships for life science companies. Mr. Conroy is an independent director of Cingulate Therapeutics, a CNS company developing ADHD therapeutics. Mr. Conroy holds a B.S. in Business Administration from Providence College. As Director, Mr. Conroy shall be compensated with stock in accordance with the mutual agreement of the Board’s compensation committee. On September 20, 2019, Jerry Casey joined the Board of Odyssey as an independent director. Jerry Casey has been a leader in the life science industry for over 30 years. Enjoying a long tenure as a senior executive at Genzyme Corporation, Mr. Casey was the driver behind Genzyme’s commercial success in the diagnostics arena, building a $175 million business which Genzyme sold to Japan-based Sekisui Chemical in 2011. Mr. Casey became the President and Chief Operating Officer of the new entity, Sekisui Diagnostics, LLC, until the end of 2014. Since leaving the company, Mr. Casey has been actively involved in several life sciences ventures, both as an advisor and an investor, while serving on multiple Boards. As Director, Mr. Casey shall be compensated with stock in accordance with the mutual agreement of the Board’s compensation committee. On October 3, 2019, the Company and Prevacus, Inc. amended the Master Agreement for a Joint Venture and Intellectual Property Purchase Agreement, dated June 26, 2019, to extend the timing of the formation of the Joint Venture to December 31, 2019. On October 23, 2019, John Gandolfo joined the Board of Odyssey as an independent director and has been elected chair of the audit committee. Mr. Gandolfo has approximately 30 years of experience as a chief financial officer of multiple rapidly growing private and publicly held companies with a primary focus in the life sciences, healthcare and medical device areas, companies such as . Mr. Gandolfo has had direct responsibility over capital raising, including five public offerings, financial management, mergers and acquisition transactions and SEC reporting throughout his professional career. Mr. Gandolfo is currently Chief Financial Officer of Eyenovia, Inc., a late-stage ophthalmic biopharmaceutical company. Mr. Gandolfo was Chief Financial Officer of Xtant Medical Holdings, Inc. from July 2010 through September 2017. He served as the Chief Financial Officer for Progenitor Cell Therapy LLC from January 2009 to June 2010. Prior to joining Progenitor, Mr. Gandolfo served as the Chief Financial Officer of Power Medical Interventions, Inc. from January 2007 to January 2009. Mr. Gandolfo was the Chief Financial Officer of Bioject Medical Technologies, Inc. He was also the Chief Financial Officer of Capital Access Network, Inc, from 2000 through September 2001, and Xceed, Inc. from 1999 to 2000. From 1994 to 1999, Mr. Gandolfo was Chief Financial Officer and Chief Operating Officer of Impath, Inc. From 1987 through 1994, he was Chief Financial Officer of Medical Resources, Inc. Mr. Gandolfo received his B.A. in business administration from Rutgers University. As Director, Mr. Gandolfo shall be compensated with stock in accordance with the mutual agreement of the Board’s compensation committee.

2. Summary of Significant Acc_2

2. Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jul. 31, 2019
Accounting Policies [Abstract]
Use of estimates	Use of estimates The preparation of financial statements in conformity with Generally Accepted Accounting Principles (“GAAP”) generally requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.
Basis of accounting	Basis of accounting The Company has not elected to adopt the option available under GAAP to measure any of its eligible financial instruments or other items at fair value. Accordingly, the Company measures all of its assets and liabilities on the historical cost basis of accounting unless otherwise required by GAAP.
Accounts Receivable	Accounts receivable Accounts receivable are carried at original invoice amount less an estimated allowance for doubtful accounts, if deemed necessary by management. An allowance for doubtful accounts is based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful accounts, if any, by identifying troubled accounts and by using historical experience applied to an aging of accounts.
Property and Equipment, Net	Property and equipment, net Property and equipment is stated at cost less accumulated depreciation. Depreciation is recorded on a straight-line basis over the estimated useful lives of the assets. For the year ended July 31, 2019 and 2018 the Company recognized depreciation expense of $552.
Beneficial Conversion Feature of convertible notes payable	Beneficial Conversion Feature of convertible notes payable The Beneficial Conversion Feature ("BCF") of a convertible note is normally characterized as the convertible portion or feature of certain notes payable that provide a rate of conversion that is below market value or in-the-money when issued. The Company records a BCF related to the issuance of a convertible note when issued and also records the estimated fair value of any warrants issued with those convertible notes. Beneficial conversion features that are contingent upon the occurrence of a future event are recorded upon the occurrence of the event. The BCF of a convertible note is measured by allocating a portion of the note's proceeds to the warrants, if applicable, and as a reduction of the carrying amount of the convertible note equal to the intrinsic value of the conversion feature, both of which are credited to additional paid-in-capital. The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on an allocated fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense.
Net loss per share	Net loss per share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. No fully diluted loss per share is presented, because it would be anti-dilutive.
Revenue recognition	Revenue recognition The Company recognizes revenue when control is transferred to the customer. For products sold through direct sales representatives, control is transferred upon shipment or upon delivery, based on the contract terms and legal requirements. Payment terms vary depending on the country of sale, type of customer, and type of product. If a contract contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative standalone selling price. Shipping and handling is treated as a fulfillment activity rather than a promised service, and therefore, is not considered a performance obligation. Taxes assessed by a governmental authority that are both imposed on, and concurrent with, a specific revenue producing transaction and collected by the Company from customers (for example, sales, use, value added, and some excise taxes) are not included in revenue. For contracts that have an original duration of one year or less, the Company uses the practical expedient applicable to such contracts and does not adjust the transaction price for the time value of money. We are not currently selling or marketing any products, as our product is in late stage development and FDA clearance to market the product will be required in order to sell in the United States.

4. Intangible Assets - Paten_2

4. Intangible Assets - Patent and Distribution Rights (Tables)	12 Months Ended
	Jul. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Future Patent Amortization	Year Ending July 31, Patents Year 1 $ 2,039,003 Year 2 2,034,003 Year 3 2,029,003 Year 4 2,029,003 Year 5 2,029,003 Thereafter 12,979,557

2. Summary of Significant Acc_3

2. Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Accounting Policies [Abstract]
Depreciation expense	$ 552	$ 552

4. Intangible Assets - Paten_3

4. Intangible Assets - Patent and Distribution Rights (Details)	Jul. 31, 2019USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Year 1	$ 2,039,003
Year 2	2,034,003
Year 3	2,029,003
Year 4	2,029,003
Year 5	2,029,003
Thereafter	$ 12,979,557

4. Intangible Assets - Paten_4

4. Intangible Assets - Patent and Distribution Rights (Details Narrative) - USD ($)	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Intangible asset, gross	$ 23,205,400
Accumulated amortization	65,830
Intangible assets, net	23,139,570
Amortization expense	$ 40,830	$ 10,000
Patent useful life	10 years 8 months 23 days
CardioMap [Member]
Intangible asset, gross	$ 18,750,000
CardioMap [Member] | Fair Value Inputs Level 2 [Member]
Intangible asset fair value	18,750,000
De Luca Patents [Member]
Intangible asset, gross	675,400
Contingent Liability	144,000
De Luca Patents [Member] | Fair Value Inputs Level 2 [Member]
Intangible asset fair value	675,400
Prevacus Patent [Member]
Intangible asset, gross	3,730,000
Prevacus Patent [Member] | Fair Value Inputs Level 2 [Member]
Intangible asset fair value	$ 3,730,000

5. Notes Payable (Details Narra

5. Notes Payable (Details Narrative)	12 Months Ended
	Jul. 31, 2019USD ($)$ / shares
Note Payable [Member]
Maturity date	Jan. 31, 2020
Interest rate	12.50%
Conversion price per share | $ / shares	$ 0.01
Convertible note payable outstanding	$ 747,608
Convertible Notes [Member]
Interest rate	7.00%
Conversion price per share | $ / shares	$ 0.01
Convertible note payable outstanding	$ 37,305
Beneficial conversion feature	$ 213,650

7. Common Stock (Details Narrat

7. Common Stock (Details Narrative) - USD ($)	3 Months Ended	4 Months Ended	5 Months Ended	6 Months Ended	11 Months Ended	12 Months Ended
	Apr. 30, 2019	May 22, 2019	Jan. 09, 2019	Jul. 31, 2019	Jun. 27, 2019	Jul. 31, 2019	Jul. 31, 2018
Stock granted for compensation, shares						72,000
Share based compensation						$ 101,417	$ 0
Amount per share				$ 0.001		$ 0.001	$ .001
Employee 1 [Member]
Stock granted for compensation, shares		10,000
Employee 2 [Member]
Stock granted for compensation, shares		10,000
Founding Stockholders [Member]
Stock returned, shares returned							60,000,000
J. Michael Redmond [Member]
Stock granted for compensation, shares						4,700,000
Share based compensation						$ 47,000
Green Energy Alternatives [Member]
Stock granted for compensation, shares						5,300,000
Vivakor [Member]
Debt converted, amount converted			$ 25,314
Debt converted, shares issued			2,531,400
Consulting Services [Member]
Stock granted for compensation, shares	100,000			305,000
Vanlandingham [Member] | Acquisition of Patent [Member]
Stock granted for acquisition of intangible assets					984,000
Vanlandingham [Member] | Director Compensation [Member]
Stock granted for compensation, shares					20,000
De Luca Agreement [Member] | Patent and Intellectual Property [Member]
Stock granted for compensation, shares					20,000
Stock granted for acquisition of intangible assets					600,000

8. Stock Based Compensation (De

8. Stock Based Compensation (Details Narrative) - Options [Member] - J. Michael Redmond [Member]	12 Months Ended
	Jul. 31, 2019$ / sharesshares
Options granted | shares	15,000,000
Fair value options granted per share | $ / shares	$ 0.25

9. Income Taxes (Details Narrat

9. Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Income Tax Disclosure [Abstract]
Net deferred tax assets	$ 260,247	$ 309,859
Net operating loss carryforwards expiration date	Dec. 31, 2035
Effective tax rate	21.00%	21.00%

10. Going Concern (Details Narr

10. Going Concern (Details Narrative) - USD ($)	Jul. 31, 2019	Jul. 31, 2018
Risks and Uncertainties [Abstract]
Operating deficit	$ (1,521,302)	$ (1,072,877)

11. Related Party Transactions

11. Related Party Transactions (Details Narrative) - shares	Jul. 31, 2019	Jul. 31, 2018
Common stock owned	86,990,400	61,414,000
Green Energy Alternatives [Member]
Common stock owned	5,300,000	5,300,000